<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endocannabinoids and cannabinoid 1 (CB(1)) receptors have been implicated in cardiac dysfunction, <z:mp ids='MP_0001845'>inflammation</z:mp>, and cell <z:hpo ids='HP_0011420'>death</z:hpo> associated with various forms of shock, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, in addition to their recognized role in the development of various <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in <z:hpo ids='HP_0001513'>obesity</z:hpo>/<z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we explored the role of CB(1) receptors in myocardial dysfunction, <z:mp ids='MP_0001845'>inflammation</z:mp>, oxidative/nitrative stress, cell <z:hpo ids='HP_0011420'>death</z:hpo>, and interrelated signaling pathways, using a mouse model of type 1 diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> was characterized by increased myocardial endocannabinoid <z:chebi fb="0" ids="2700">anandamide</z:chebi> levels, oxidative/nitrative stress, activation of p38/Jun NH(2)-terminal kinase (JNK) <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases (MAPKs), enhanced <z:mp ids='MP_0001845'>inflammation</z:mp> (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α, interleukin-1β, cyclooxygenase 2, intracellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1, and vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1), increased expression of CB(1), advanced glycation end product (AGE) and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptors (receptor for advanced glycation end product [RAGE], <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor type 1 [AT(1)R]), p47(phox) <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase subunit, β-myosin heavy chain isozyme switch, accumulation of AGE, <z:mp ids='MP_0003045'>fibrosis</z:mp>, and decreased expression of sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA2a) </plain></SENT>
<SENT sid="3" pm="."><plain>Pharmacological inhibition or genetic deletion of CB(1) receptors attenuated the <z:mp ids='MP_0002055'>diabetes</z:mp>-induced cardiac dysfunction and the above-mentioned pathological alterations </plain></SENT>
<SENT sid="4" pm="."><plain>Activation of CB(1) receptors by endocannabinoids may play an important role in the pathogenesis of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> by facilitating MAPK activation, AT(1)R expression/signaling, AGE accumulation, oxidative/nitrative stress, <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, CB(1) receptor inhibition may be beneficial in the treatment of diabetic cardiovascular complications </plain></SENT>
</text></document>